Literature DB >> 23733274

Comparison of different measures of diffusing capacity for carbon monoxide (DLCO) in systemic sclerosis.

Marie Hudson1, Deborah Assayag, Melissa Caron, Benjamin D Fox, Andrew Hirsch, Russell Steele, Rebecca Gaudreau-Taillefer, Solène Tatibouet, Lawrence Rudski, Murray Baron.   

Abstract

In systemic sclerosis (SSc), impaired diffusing capacity for carbon monoxide (DLCO) can indicate interstitial lung disease (ILD), pulmonary hypertension (PH), and/or other disease manifestations, including anemia. We undertook this study to compare the various measures of DLCO in the setting of a complex disease like SSc. We analyzed the pulmonary function tests of a cohort of SSc subjects, as a whole and among subjects with isolated PH and ILD separately. Associations were assessed using Spearman correlation coefficients, Student's t tests, and F tests by one-way ANOVA. P values <0.05 were considered statistically significant. This study included 225 subjects (mean age, 57 years; 88 % women; mean disease duration, 9.6 years; 32 % with diffuse disease, 44 % with ILD, and 17 % with PH). Mean percent predicted DLCO values were 75 % for DLCOsb and 83 % for DLCOrb. Adjustment for alveolar volume (VA) resulted in near normalization of both DLCOsb/VAsb (91 %) and DLCOrb/VArb (91 %). Subjects with ILD had significantly lower DLCOsb but not DLCOsb/VAsb, whereas those with PH had significantly lower DLCOsb and DLCOsb/VAsb. Among the various measures of DLCO, DLCOsb had the strongest and most consistent associations with clinical outcomes of interest. Adjusting for alveolar volume dampened the associations except with PH, with which DLCOsb/VAsb was more strongly associated than DLCOsb. Low DLCOsb is the most sensitive measure to detect abnormalities in gas exchange in SSc but reflects both parenchymal lung disease and pulmonary vascular disease. Low DLCOsb/VAsb is more specific for pulmonary vascular disease and should be the preferred measure of gas exchange in SSc.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23733274     DOI: 10.1007/s10067-013-2301-8

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  37 in total

1.  Comparison of Doppler echocardiography and right heart catheterization to assess pulmonary hypertension in systemic sclerosis.

Authors:  C P Denton; J B Cailes; G D Phillips; A U Wells; C M Black; R M Bois
Journal:  Br J Rheumatol       Date:  1997-02

Review 2.  Standardization of the measurement of transfer factor (diffusing capacity). Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society.

Authors:  J E Cotes; D J Chinn; P H Quanjer; J Roca; J C Yernault
Journal:  Eur Respir J Suppl       Date:  1993-03

3.  Isolated diffusing capacity reduction in systemic sclerosis.

Authors:  V D Steen; G Graham; C Conte; G Owens; T A Medsger
Journal:  Arthritis Rheum       Date:  1992-07

4.  Prediction of pulmonary hypertension related to systemic sclerosis by an index based on simple clinical observations.

Authors:  Christophe Meune; Jérôme Avouac; Paolo Airò; Lorenzo Beretta; Philippe Dieudé; Karim Wahbi; Paola Caramaschi; Kiet Tiev; Susanna Cappelli; Elisabeth Diot; Alessandra Vacca; Jean-Luc Cracowski; Jean Sibilia; André Kahan; Marco Matucci-Cerinic; Yannick Allanore
Journal:  Arthritis Rheum       Date:  2011-09

5.  Assessment of pulmonary arterial hypertension in patients with systemic sclerosis: comparison of noninvasive tests with results of right-heart catheterization.

Authors:  Vivien M Hsu; Abel E Moreyra; Alan C Wilson; Meir Shinnar; Daniel M Shindler; Julianne E Wilson; Ami Desai; James R Seibold
Journal:  J Rheumatol       Date:  2008-01-15       Impact factor: 4.666

6.  Predictors of interstitial lung disease in early systemic sclerosis: a prospective longitudinal study of the GENISOS cohort.

Authors:  Shervin Assassi; Roozbeh Sharif; Robert E Lasky; Terry A McNearney; Rosa M Estrada-Y-Martin; Hilda Draeger; Deepthi K Nair; Marvin J Fritzler; John D Reveille; Frank C Arnett; Maureen D Mayes
Journal:  Arthritis Res Ther       Date:  2010-09-02       Impact factor: 5.156

7.  The value of the Health Assessment Questionnaire and special patient-generated scales to demonstrate change in systemic sclerosis patients over time.

Authors:  V D Steen; T A Medsger
Journal:  Arthritis Rheum       Date:  1997-11

8.  Prevalence of pulmonary arterial hypertension in an Australian scleroderma population: screening allows for earlier diagnosis.

Authors:  S Phung; G Strange; L P Chung; J Leong; B Dalton; J Roddy; J Deague; D Playford; M Musk; E Gabbay
Journal:  Intern Med J       Date:  2008-11-03       Impact factor: 2.048

9.  Bronchoalveolar lavage cellular profiles in patients with systemic sclerosis-associated interstitial lung disease are not predictive of disease progression.

Authors:  Nicole S L Goh; Srihari Veeraraghavan; Sujal R Desai; Derek Cramer; David M Hansell; Christopher P Denton; Carol M Black; Roland M du Bois; Athol U Wells
Journal:  Arthritis Rheum       Date:  2007-06

10.  Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach.

Authors:  D Mukerjee; D St George; B Coleiro; C Knight; C P Denton; J Davar; C M Black; J G Coghlan
Journal:  Ann Rheum Dis       Date:  2003-11       Impact factor: 19.103

View more
  4 in total

1.  Longitudinal change during follow-up of systemic sclerosis: correlation between high-resolution computed tomography and pulmonary function tests.

Authors:  Aldo Carnevale; Mario Silva; Elisa Maietti; Gianluca Milanese; Marta Saracco; Simone Parisi; Elena Bravi; Fabio De Gennaro; Eugenio Arrigoni; Flavio Cesare Bodini; Enrico Fusaro; Carlo Alberto Scirè; Nicola Sverzellati; Alarico Ariani
Journal:  Clin Rheumatol       Date:  2020-09-03       Impact factor: 2.980

2.  Quantitative volumetric assessment of pulmonary involvement in patients with systemic sclerosis.

Authors:  Mehmet Güli Çetinçakmak; Cemil Göya; Cihad Hamidi; Güven Tekbaş; Özlem Abakay; İbrahim Batmaz; Salih Hattapoğlu; Alpaslan Yavuz; Aslan Bilici
Journal:  Quant Imaging Med Surg       Date:  2016-02

3.  Automatic quantitative computed tomography measurement of longitudinal lung volume loss in interstitial lung diseases.

Authors:  Mouhamad Nasser; Marion Colevray; Salim A Si-Mohamed; Olivier Nempont; Pierre-Jean Lartaud; Anna Vlachomitrou; Thomas Broussaud; Kais Ahmad; Julie Traclet; Vincent Cottin; Loic Boussel
Journal:  Eur Radiol       Date:  2022-01-14       Impact factor: 7.034

4.  Expression of the Autoantigen Topoisomerase-1 is Enriched in the Lung Tissues of Patients With Autoimmune Interstitial Lung Disease: A Case Control Study.

Authors:  Tricia R Cottrell; Frederic Askin; Marc K Halushka; Livia Casciola-Rosen; Zsuzsanna H McMahan
Journal:  ACR Open Rheumatol       Date:  2020-10-29
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.